Redirecting to https://apnews.com/press-release/globenewswire-mobile/junshi-biosciences-announces-primary-endpoints-met-in-final-analysis-of-phase-3-study-for-perioperative-toripalimab-plus-chemotherapy-for-resectable-stage-ii-iii-nsclc-1fecf634b416a3f5323fe41c3e770357